Phaseline

Companies › Vertex Pharmaceuticals

Vertex Pharmaceuticals: clinical trials, targets and expected readouts

17 active drug programs in 38 registered trials: 19 Phase 3, 9 Phase 1, 5 Phase 2, 5 Phase 4; Respiratory, Neurology, Genitourinary, Metabolic and endocrine; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Suzetrigine (SUZ, VX-548)
Nav1.9 sodium channel inhibitor
Ion channelsPhase 4Pain; Diabetic Peripheral Neuropathic Pain; Opioid Consumption, Postoperative; Bariatric Surgery …Jan 2027
Ivacaftor
Cystic fibrosis transmembrane conductance regulator positive modulator; Cystic fibrosis transmembrane conductance regulator activator
CFTRPhase 3Cystic Fibrosis; Cystic Fibrosis (CF)Apr 2027
Tezacaftor
Cystic fibrosis transmembrane conductance regulator positive modulator
CFTRPhase 3Cystic Fibrosis; Cystic Fibrosis (CF)Apr 2027
Exagamglogene Autotemcel (CTX001)
B-cell lymphoma/leukemia 11A gene editing negative modulator
BCL11APhase 3Sickle Cell Disease; Beta-ThalassemiaJun 2027
VX-880 (Zimislecel, formerly STx-02)
Engineered insulin-producing cells derived from human pluripotent stem cells
–Phase 3Type 1 Diabetes; Diabetes Mellitus, Type 1Sep 2027
VX-017
Immune modulatory cell therapy
–Phase 3Diabetes Mellitus, Type 1Dec 2027
VX-121/TEZ/D-IVA
CFTR modulator combination: VX-121 (CFTR potentiator) + tezacaftor (CFTR corrector) + deut
CFTRPhase 3Cystic Fibrosis–
VX-407
PKD1 gene variant-targeted therapy
–Phase 2Autosomal Dominant Polycystic Kidney Disease (ADPKD)Dec 2026
VX-993
Selective sodium channel inhibitor
–Phase 2Diabetic Peripheral Neuropathic PainMar 2027
VX-147
APOL1 inhibitor
APOL1Phase 2Proteinuric Kidney DiseaseJun 2028
Povetacicept–Phase 2Primary Membranous Nephropathy; Myasthenia Gravis, GeneralizedDec 2028
VX-670–Phase 1Myotonic Dystrophy Type 1 (DM1)Feb 2027
VX-433–Phase 1Narcolepsy Type 1 (NT1)Mar 2027
VX-264
Allogeneic human stem cell-derived islets
–Phase 1Type 1 DiabetesMar 2027
VX-272–Phase 1Cystic FibrosisJun 2027
VX-581
CFTR modulator (specific mechanism not stated)
–Phase 1Cystic FibrosisJul 2027
VX-522
mRNA therapy encoding CFTR
CFTRPhase 1Cystic Fibrosis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05668741VX-522Phase 1Cystic FibrosisRespiratoryApr 2026
NCT07813039VX-581Phase 1Cystic FibrosisRespiratoryOct 2026
NCT05444257VX-121/TEZ/D-IVAPhase 3Cystic FibrosisRespiratoryOct 2026
NCT07868926VX-407Phase 1Autosomal Dominant Polycystic Kidney Disease (ADPKD)GenitourinaryDec 2026
NCT07539623Suzetrigine (SUZ, VX-548)Phase 3Bariatric SurgeryCardiovascularDec 2026
NCT06696443Suzetrigine (SUZ, VX-548)Phase 3Diabetic Peripheral Neuropathic PainNeurologyJan 2027
NCT07538570Suzetrigine (SUZ, VX-548)Phase 4PainOtherJan 2027
NCT06185764VX-670Phase 1Myotonic Dystrophy Type 1 (DM1)NeurologyFeb 2027
NCT07548385Suzetrigine (SUZ, VX-548)Phase 3Total Knee Replacement SurgeryOtherFeb 2027
NCT07584434VX-433Phase 1Narcolepsy Type 1 (NT1)NeurologyMar 2027
NCT07792408VX-407Phase 1Autosomal Dominant Polycystic Kidney Disease (ADPKD)GenitourinaryMar 2027
NCT05791201VX-264Phase 1Type 1 DiabetesMetabolic and endocrineMar 2027
NCT06619860VX-993Phase 2Diabetic Peripheral Neuropathic PainNeurologyMar 2027
NCT05331183TezacaftorPhase 3Cystic FibrosisRespiratoryApr 2027
NCT07231419Suzetrigine (SUZ, VX-548)Phase 3Diabetic Peripheral Neuropathic PainNeurologyApr 2027
NCT05331183IvacaftorPhase 3Cystic FibrosisRespiratoryApr 2027
NCT06628908Suzetrigine (SUZ, VX-548)Phase 3Diabetic Peripheral Neuropathic PainNeurologyMay 2027
NCT05329649Exagamglogene Autotemcel (CTX001)Phase 3Sickle Cell DiseaseHematologyJun 2027
NCT05477563Exagamglogene Autotemcel (CTX001)Phase 3Beta-ThalassemiaHematologyJun 2027
NCT07672015Suzetrigine (SUZ, VX-548)Phase 4Opioid Consumption, PostoperativeOtherJun 2027
NCT07437105VX-272Phase 1Cystic FibrosisRespiratoryJun 2027
NCT07283770VX-581Phase 1Cystic FibrosisRespiratoryJul 2027
NCT07525219Suzetrigine (SUZ, VX-548)Phase 3Analgesic EfficacyOtherJul 2027
NCT07161037VX-407Phase 2Autosomal Dominant Polycystic Kidney Disease (ADPKD)GenitourinaryJul 2027
NCT06832410VX-880 (Zimislecel, formerly STx-02)Phase 3Type 1 DiabetesMetabolic and endocrineSep 2027
NCT06460506TezacaftorPhase 3Cystic FibrosisRespiratorySep 2027
NCT07226700Suzetrigine (SUZ, VX-548)Phase 3Total Hip Arthroplasty (THA)OtherNov 2027
NCT05356195Exagamglogene Autotemcel (CTX001)Phase 3Beta-ThalassemiaHematologyNov 2027
NCT04786262VX-017Phase 3Diabetes Mellitus, Type 1Metabolic and endocrineDec 2027
NCT04786262VX-880 (Zimislecel, formerly STx-02)Phase 3Diabetes Mellitus, Type 1Metabolic and endocrineDec 2027
NCT07809867TezacaftorPhase 4Cystic Fibrosis (CF)RespiratoryApr 2028
NCT05312879VX-147Phase 2Proteinuric Kidney DiseaseGenitourinaryJun 2028
NCT07204275PovetaciceptPhase 2Primary Membranous NephropathyGenitourinaryDec 2028
NCT07864896Suzetrigine (SUZ, VX-548)Phase 3Total Knee Arthroplasty (TKA)OtherJan 2029
NCT07501702PovetaciceptPhase 2Myasthenia Gravis, GeneralizedNeurologyMar 2029
NCT04602468TezacaftorPhase 4Cystic FibrosisGastroenterologyJul 2029
NCT05422222TezacaftorPhase 3Cystic FibrosisRespiratoryJun 2030
NCT07148739IvacaftorPhase 4Cystic Fibrosis (CF)RespiratoryDec 2030

From the company's SEC filings

Cash of $218m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CFTR (4) BCL11A (1) Ion channels (1) APOL1 (1)

Companies with the same targets

Xenon Pharmaceuticals Praxis Precision Medicines Napo Pharmaceuticals 4D Molecular Therapeutics ReCode Therapeutics Napo Therapeutics Qanatpharma Krystal Biotech Boehringer Ingelheim Arcturus Therapeutics

Companies built like this

Valenta Pharm JSC Biogen Alnylam Pharmaceuticals Chiesi Farmaceutici Ionis Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.